PRCT Profile
PROCEPT BioRobotics Corporation is a leading player in the field of surgical robotics, specializing in innovative solutions for urology.
The company is recognized for developing, manufacturing, and marketing the AquaBeam Robotic System, a cutting-edge, image-guided robotic platform designed for minimally invasive urologic procedures. The AquaBeam system is primarily used in the treatment of benign prostatic hyperplasia (BPH), offering a high-precision approach to addressing this common condition.
The company’s flagship technology, the AquaBeam Robotic System, is engineered to perform Aquablation therapy, a novel treatment for men experiencing lower urinary tract symptoms associated with BPH. This therapy utilizes the AquaBeam’s advanced imaging and robotic capabilities to deliver a targeted and effective solution for symptom relief, enhancing patient outcomes through reduced procedural invasiveness and improved precision.
As of December 31, 2021, PROCEPT BioRobotics had installed 130 AquaBeam Robotic Systems globally, with 78 units located within the United States. This growing install base highlights the increasing adoption of PROCEPT BioRobotics’ technology in medical institutions and underscores the company’s expanding influence in the field of urologic surgery.
Founded in 2007 and headquartered in Redwood City, California, PROCEPT BioRobotics is committed to advancing the field of robotic-assisted surgery. The company continues to focus on expanding its product offerings and enhancing its technological capabilities to meet the evolving needs of urologists and their patients. With its innovative approach and dedication to improving surgical outcomes, PROCEPT BioRobotics remains at the forefront of transformative medical technologies.
|
